/
- Government Regulation Pharmaceutical Pricing and Reimbursement for further details. In many countries outside the U.S., government-sponsored healthcare systems are the primary payors for drugs.
The business is unprofitable at the operating level (-23.48% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 6.5% YoY. The question is whether this is cyclical or a structural shift.
Insufficient data to identify specific risks. Treat any missing metrics as a data gap, not a clean bill of health.
Profitability & Returns
Revenue (TTM)
$217M
▼ -6.5% YoY
Net Income (TTM)
-$34M
▲ +52.8% YoY
Op. Margin
-20.64%
▲ +16.7pp YoY
ROIC
-7.57%
▲ +5.5pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$26M
▲ +121.7% YoY
Op. Cash Flow (TTM)
$26M
▲ +121.7% YoY
Net Debt
-$300M
Net Cash Position
Cash & Equiv.
$308M
5Y CAGR: -19.0%
Continue Research